

# Trisomy 21 and early brain development

Tarik F. Haydar<sup>1</sup> and Roger H. Reeves<sup>2</sup>

<sup>1</sup> Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118

<sup>2</sup> Department of Physiology and the Institute for Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205

**Trisomy for human chromosome 21 (Hsa21) results in Down syndrome (DS). The finished human genome sequence provides a thorough catalog of the genetic elements whose altered dosage perturbs development and function in DS. However, understanding how small alterations in the steady state transcript levels for <2% of human genes can disrupt development and function of essentially every cell presents a more complicated problem. Mouse models that recapitulate specific aspects of DS have been used to identify changes in brain morphogenesis and function. Here we provide a few examples of how trisomy for specific genes affects the development of the cortex and cerebellum to illustrate how gene dosage effects might contribute to divergence between the trisomic and euploid brains.**

## Introduction

Trisomy for human chromosome 21 (Hsa21) causes Down syndrome in approximately one out of every 800 live births [1]. Individuals with DS show a wide range of effects in many organ systems, some of which are congenital and some of which are progressive. These include cardiac malformations [2], gastrointestinal anomalies [3], craniofacial and skeletal anomalies [4,5], and contrasting cancer phenotypes, which include an increased frequency of childhood leukemia and reduced prevalence of many types of cancer in adults [6,7]. There is broad variability in both the occurrence (penetrance) and severity (expressivity) of these phenotypes across the DS population. Since all individuals with DS have some degree of intellectual disability (ID), it is the most frequent genetic cause of ID, with intelligence quotients (IQs) that can range from mild to severe; the mean IQ in DS is ~50 [8]. Studies in animal models and in people have uncovered cellular, physiological and functional changes that contribute to the etiology of cognitive deficits and provide the basis for emerging clinical trials aimed at improving cognitive abilities in DS [9–11].

Central nervous system (CNS) abnormalities in DS seem to arise from a combination of abnormal development and functional changes that result directly from overexpression of genes in trisomic cells. Neuropathological changes found during late prenatal development in DS include delayed and disorganized cortical lamination [12], a smaller and hypocellular hippocampal dentate gyrus [13]

and hypomorphic cerebellum [14–18]. In the cerebral cortex, pyramidal neurons possess smaller dendritic arborizations [19–21] and there are fewer synapses in the prenatal DS brain [22,23]. These deficits are followed postnatally by degeneration of cortical pyramidal neurons [24], profound dendrite and synapse abnormalities [19,21,24,25] and reductions in the total number of neurons in the hippocampus and cerebral cortex [13,26]. Cerebellar development is delayed and ultimately appears to terminate prematurely. These findings indicate that prenatal changes in CNS growth and differentiation underlie many of the pathological abnormalities associated with ID in DS.


Several fundamental cellular growth mechanisms that are crucial for development are abnormal in DS. Specific changes have been reported for the cell cycle rate and progression in multiple organ systems, which suggests that the altered kinetics of cell production may contribute to many phenotypes. DNA synthesis and doubling times are both slower in DS fibroblasts [27,28] and DS cerebral cortex contains less cyclin-dependent kinase [29], which are indicative of lower replication rates. Recent studies have also shown that proliferation is abnormal in the developing DS forebrain [30] and cerebellum [31]. Many details regarding the molecular pathways underlying these phenotypes and how altered brain formation may lead to ID remain unclear. Here, we consider emerging data from mouse models of DS that demonstrate key deficiencies in neural stem and progenitor cell expansion and changes in the resulting specification of post-mitotic neurons and glial cells in the developing CNS. Elucidating the DS developmental brain abnormalities at the molecular level is essential for understanding the etiology of the postnatal cognitive disabilities.

## Mouse models of DS and gene effects

Cell intrinsic abnormalities caused by trisomy may be amplified by aberrant cell–cell interactions during development. These cascading effects pose challenges to understanding and ultimately treating the structural and functional defects observed in the postnatal brain [32,33]. The complexity of these relationships in many organ systems cannot be recapitulated in a test tube or cell culture.

Mouse models of DS are trisomic for chromosome regions that show conserved synteny with Hsa21 (Figure 1) [34]. In comparison to human, orthologous mouse chromosome regions show minor differences in gene

Corresponding authors: Haydar, T.F. (thaydar@bu.edu); Reeves, R.H. (reeves@jhmi.edu)




**Figure 1. Genetic maps of trisomic mouse models.** The Hsa21 homologous region in the mouse is Mmu16. This region contains orthologs of approximately half the genes on Hsa21 [41]. The gene content of segmental trisomies occurring as translocations or duplications in the mouse models discussed in this review (i.e. Ts65Dn, Ts1Cje and Ts1Rhr) are shown, with the approximate number of genes contained in these regions given in parentheses. Some of the individual genes within this region are listed, with the specific genes discussed in this review highlighted in red [35,113,114]. Gene positions are noted within parentheses; gene labels are not positioned to scale.

content and in the structures of conserved genes, although there are undoubtedly important differences in gene regulation. However, the occurrence of DS-like outcomes in mice trisomic for orthologs of Hsa21 genes has been established and refined to a great degree using the Ts65Dn mouse model [35]. Increasingly sophisticated mouse models of DS have been developed through cell and

chromosome engineering in the last few years, including mice with mosaic trisomy for human chromosome 21 [36] and with trisomy for all mouse orthologs of Hsa21 [37]. These models and their genetic and molecular validation have been reviewed extensively [38–40].

Despite significant parallels between DS and mouse models, a mouse is not a human being and the consequence



**Figure 2. Comparison of altered cellular and anatomical alterations observed in prenatal brain from trisomic mouse models and postnatal human Down syndrome (DS) brain. (a)** Evidence from several trisomic mouse models of DS indicates altered production of excitatory and inhibitory forebrain neurons in the neocortex [59,60], delayed development of the cortical white matter [59], and defective synapse formation/maintenance [58]. In addition, supernumerary interneurons (INs) in the hippocampus result in overinhibition of pyramidal neurons [58] and may be involved in the observed alterations in synaptic plasticity (i.e. long-term potentiation/depression, LTP/LTD) [83,84]. Defective proliferation of the granule cell precursors also reduces the overall volume and neuronal constitution of the cerebellum [99]. **(b)** Many of these abnormalities found during mouse development presumably underlie morphological and behavioral outcomes in the human DS brain [12–15,17–19,115,116]. The magnified area depicts the hippocampus. Abbreviations: MGE, medial ganglionic eminence; PARV, parvalbumin; SOM, somatostatin.

of trisomy in non-human species is not Down syndrome. Nevertheless, fundamental processes of development and function are conserved across mammals and beyond, and dosage changes for orthologous genes will, in many cases, have comparable effects on outcomes (Figure 2). The proper focus for model studies, then, is on evolutionarily conserved processes and the mechanisms by which they are perturbed. Given a sophisticated understanding of the advantages and limitations of the genetic basis for DS versus trisomy in the mouse, the utility of a model depends

on both the precision with which phenotypes can be determined and the strength of those comparisons to the situation in people. Human phenotypes are normally limiting in this context, because the possibility for intrusive studies in animal models provides for a far more sensitive and comprehensive substrate for assessment.

Ts65Dn mice have a number of well-characterized neural phenotypes affecting learning, memory, brain morphology, synaptogenesis, electrophysiology and neurochemical properties of the brain. They undergo neurodegenerative

### Box 1. Hsa21 genes implicated in brain structure and function

Virtually any trisomic gene could potentially affect development or function in the CNS. Examples include an enzyme that changes metabolic rates, a growth factor signal that is overexpressed at a critical time in development, or a transcription factor whose increased expression results in increased transcript levels for hundreds of genes [32,33]. There are many genes on chromosome 21 whose functions in the CNS suggest more specific possible contributions to maldevelopment in DS, and these have been considered at length (see e.g. [117] and a recent meta-analysis of expression data in trisomy [118]). Several of the many genes that have been proposed to affect the CNS when trisomic are mentioned here; however, this is by no means intended as a comprehensive overview of gene dosage effects in DS.

#### (i) Cell-surface molecules

A number of these are encoded on Hsa21, including cell adhesion molecules, neural cell adhesion molecule 2 (NCAM2), Down syndrome cell adhesion molecule (DSCAM) and synaptotagmin (SYNJ1), which all have potential roles in neuronal development and function. Perhaps one of the most extensively studied cell-surface molecules encoded on Hsa21 is APP. Mutations in the *APP* gene are associated with familial Alzheimer's disease (AD), and AD occur in all individuals with trisomy 21. In addition to its role in plaque formation in the aging brain, increased expression of *APP* plays a role in the degeneration of cholinergic neurons in the basal forebrain of a mouse model of DS [119], and it probably plays an important role in learning and memory processes [113].

#### (ii) Channels and transporters

Multiple ion channels and transporters that are expressed in the brain are encoded on Hsa21. These include GRIK1, an ionotropic glutamate receptor subunit that is implicated in cognition and in a number of neurological disorders [120]. SLC5A3, solute carrier family 5 (sodium/

myo-inositol cotransporter) member 3, is a member of a family of inositol transporters. Inositol transport is an essential function in many cells and tissues, including the brain, but the primary neuronal effects attributed to SLC5A3 are in the peripheral nervous system [121]. GIRK2, a G-protein-coupled inwardly rectifying potassium channel, was initially identified because a mutation in the gene encoding it (known as the mouse *weaver* mutation) caused early loss of cerebellar GCPs, resulting in ataxia [122]. Altered *Girk2* expression may also contribute to cognitive deficits in DS by interfering with GABA<sub>B</sub> receptor signaling in the hippocampus [123,124].

#### (iii) Transcription factors

Elevated expression of transcription factors would obviously have a direct effect on many dozens or hundreds of additional genes, most of which will be disomic. Thirteen transcription factors and transcription modifiers are encoded on Hsa21. Some of the better-studied transcription factors include OLIG1/2, GABP ALPHA, RUNX1, ERG, ETS2, BACH1, SON and NRIP1 (see Figure 1 for gene details).

#### (iv) Other genes

Some other genes of interest on Hsa21 include regulator of calcineurin 1 (*RCAN1*), which encodes a negative regulator of calcineurin. Downregulation of calcineurin by RCAN1 affects calcineurin-dependent gene transcription through inhibition of NFATc translocation to the nucleus [125]. RCAN1 is highly expressed in cardiac and skeletal muscle, but it has been posited that interactions with DYRK1A in many tissues during development perturb NFATC (nuclear factor of activated T-cells, cytoplasmic) functions and potentially contribute to multiple aspects of DS [125]. Super oxide dismutase 1 (*SOD1*) is another gene that has been extensively researched in DS and, similar to *APP*, it has been associated with other neurological diseases, including amyotrophic lateral sclerosis and Parkinson's disease [126].

processes that affect structure and function as they age. Many of these effects parallel changes that are observed in the DS brain (Figure 2) [41]. A number of trisomic genes have been implicated in various aspects of brain development and function (Box 1); however, such findings are complicated by the fact that behavioral tests with the same name are seldom performed in the same way [41]. Here we consider just three genes – the oligodendrocyte transcription factors *Olig1* and *2*, and dual-specificity tyrosine phosphorylation-regulated kinase 1A (*Dyrk1a*) – as examples of how overexpression due to trisomy can affect the function and development of the hippocampus and cortex. We also discuss the anomalous response of trisomic cerebellar precursor neurons to the signaling pathway mediated by the sonic hedgehog (SHH) growth factor. This canonical pathway plays a significant role in trisomic mice, but is based on disomic genes. The trisomic gene(s) that cause the aberrant response have not yet been identified.

### Specification and mapping of forebrain neurons


The function of brain circuits, and the motor and cognitive paradigms they subserve, depends on the proper ratio of excitatory and inhibitory neurons within the network. Fine tuning of this ratio prevents excess excitation and/or inhibition in the neuronal pathways and is important for proper development [42–45]. Excitatory glutamatergic neurons and inhibitory GABAergic neurons converge on the forebrain through a surprisingly diverse but precisely ordered sequence of developmental steps; faithful execution of each of these steps is necessary for a normally

functioning cortex. The proper numbers of neurons must first be generated and specified to the correct cell type; they must then migrate to their appropriate position, which is often millimeters to centimeters away from the site of origin.

Excitatory neurons are generated from precursors in the dorsal telencephalic ventricular and subventricular zones (VZ and SVZ) and migrate radially into the neocortical wall [46]. Most inhibitory interneurons are born in the ventral VZ of the ganglionic eminence and populate the cortex and hippocampus via tangential migration [47–51]. Despite their distinct sites of origin, cortical excitatory and inhibitory neurons born on the same embryonic day occupy the same laminar positions within the neocortex [46,52–56]. Thus, both their allocation within the neocortex and their temporal programs of differentiation must be tightly coordinated. In individuals with DS and in mouse models, deficient production and allocation of neuronal cell types are markedly abnormal in several key regions, including the dorsal and ventral telencephalon and the cerebellum. Together, these studies suggest that cellular defects during the production phase of brain development alter the ratios of different types of neurons and may be key contributors to the eventual cognitive deficits in DS.

#### Dorsal forebrain phenotype: underproduction of excitatory neurons

Owing to the delayed development and laminar disorganization evident in late gestational and perinatal DS forebrain, it is now clear that the mechanisms controlling both



**Figure 3. Abnormal cortical development in mouse models of Down syndrome (DS) results in an altered ratio of excitatory and inhibitory neurons.** Evidence from the Ts65Dn mouse model of DS indicates that longer cell-cycle duration (Tc) in the ventricular and subventricular zones (VZ and SVZ, respectively) leads to reduced overall production of excitatory neurons (green cells, ENs) at the cortical plate (CP) [59]. This delayed arrival and differentiation of excitatory neurons results in a thinner intermediate zone (IZ) containing the axon tracts of descending and ascending cortical inputs. In addition, overexpression of the *Olig1* and *Olig2* transcription factor genes in the germinal zones of the ventral telencephalon leads to increased production of parvalbumin- and somatostatin-expressing interneurons (red cells, INs) in the cerebral cortex and hippocampus [99]. Collectively, these defects change the ratio of excitatory:inhibitory neurons during prenatal forebrain neurogenesis. Abbreviation: MN, migrating neuron.

embryonic production and allocation of neurons are disturbed in DS. Excitatory neurons are particularly affected and synapses with and among these cells are fewer than in euploid brain. How does this arise? Several groups have now quantitatively determined that excitatory neurons are underproduced by the neural stem and progenitor cells in the embryonic VZ in DS fetal brain [30,57] and in the Ts65Dn mouse [58]. Not only is the cell cycle of VZ cells lengthened, but the commitment of new neurons is also delayed. This combination results in fewer new neurons and a reduction in the expansion of the maturing cortical layers. The delay in neuronal differentiation also affects the development of axonal tracts in white matter [59–61]. This shortfall in excitatory neurons is maintained after birth as neurons of the cerebral cortex begin to establish synapses with both near and distant targets (Figure 3). Proper synaptic integration of neurons is predicated on their readiness (i.e. timely arrival and proper differentiation state), so one major hypothesis arising from these studies is that the reductions and delays in neurogenesis may prevent or curtail crucial windows of development and set the stage for subsequent defects in synapse formation and consolidation.

One of the genes that is triplicated in DS and in several mouse models, and which is now strongly implicated in dorsal telencephalic VZ proliferation, is *DYRK1A* (formerly called *minibrain*) [62–66]. This gene encodes a dual-specificity tyrosine phosphorylation-regulated kinase that is strongly expressed in neural structures, especially within neural precursor populations during embryonic neurogenesis [67–69]. Haploinsufficiency or truncation of *DYRK1A* leads to brain abnormalities in mice and to microcephaly in

humans [70,71]. This kinase interacts with a wide variety of growth factors, transcription factors and cell-cycle regulatory proteins known for their roles in neural cell proliferation and specification. These include fibroblast growth factor  $\beta$ , cyclin D1, the E2F family of transcription factors (E2F1), the mammalian homolog of the *Drosophila* transcription factor Snf5-related 1 (SNR1), the type I transmembrane protein notch, neuron-restrictive silencer factor (NRSF, also known as REST) and the 53-kDa tumor suppressor protein p53 [72–78].

Mice that overexpress *Dyrk1a*, either constitutively and promiscuously as a transgene with a leaky metallothionein promoter or under natural promoters in BAC and YAC transgenic mice, display subtle motor defects and deficits in spatial learning memory [79]. This has been interpreted to suggest that *Dyrk1a* overexpression may perturb developmental pathways and lead to postnatal neurodevelopmental delays [80,81]. DYRK1A is asymmetrically localized to the VZ precursors that divide to give rise to neuronal-committed progenitors or to neurons directly [68]. It has been hypothesized that the increased gene dosage and overexpression in DS may lead to precocious neuronal differentiation and depletion of the neural precursor pool during neurogenesis [82]. Indeed, *Dyrk1a* overexpression in embryonic VZ precursors, induced by *in utero* electroporation (IUE), inhibits proliferation and alters neuronal differentiation [77]. The latter study demonstrated that IUE-induced overexpression rapidly depletes the VZ proliferative pool by causing precocious neuronal differentiation. Although the committed neurons were still able to migrate to the appropriate cortical layer, the overall production capacity of the germinal zones was decreased

by this transient overexpression paradigm. The neurogenesis block induced by *Dyrk1a* overexpression is due, at least in part, to nuclear export and degradation of cyclin D1 [77]. Further studies of the multiple roles of *Dyrk1a* in brain development are needed to explain how overexpression contributes to the brain growth and function phenotypes of DS.

#### *Ventral forebrain phenotype: overproduction of inhibitory neurons*

In addition to the underproduction of cortical excitatory neurons caused by the dorsal phenotype, it is now clear that specific classes of forebrain inhibitory interneurons are overproduced during embryonic development in the Ts65Dn mouse model, which further alters the excitatory/inhibitory neuron ratio in Ts65Dn [58]. In particular, a substantial increase in the numbers of parvalbumin (PARV)- and somatostatin (SOM)-expressing interneurons occurs in the dorsal neocortex and hippocampus in both embryonic and postnatal stages (Figure 3). These supernumerary interneurons result from elevated rates of cell production by precursors in the ganglionic eminence in the ventral telencephalon. Moreover, neurogenesis is specifically increased only in the medial ganglionic eminence (MGE) – the specific germinal zone for the PARV- and SOM-expressing interneurons – and not in the progenitors of the lateral and caudal ganglionic eminence, which generate other groups of unaffected interneurons. One physiological consequence of these overabundant inhibitory neurons is increased inhibition of forebrain pyramidal neurons.

These results represent the first cellular evidence of the source of overinhibition in the Ts65Dn forebrain. Excess inhibitory input in the hippocampus may lead to deficiencies in synaptic plasticity with associated cognitive deficits affecting learning and memory [83,84]. These hippocampal circuits are now a target for therapies to improve cognition in DS [9,11]. For example, blocking of inhibitory GABAergic neurotransmission pharmacologically in adult Ts65Dn mice ameliorated the spatial learning deficits in these animals [85]. Thus, it is clear that increased inhibition may be a key mediator of cognitive dysfunction in DS.

During prenatal development, MGE precursors are bipotential and can divide to generate either inhibitory interneurons or oligodendrocytes based on the expression of a combinatorial code of transcription factors [86–88]. Two of the major transcription factors expressed during MGE neurogenesis are *Olig1* and *Olig2*. Both of these genes are triplicated and overexpressed in MGE of Ts65Dn mice and people with DS. By crossing *Olig1*<sup>+/-</sup>;*Olig2*<sup>+/-</sup> double heterozygotes to Ts65Dn females, the gene dosage of just *Olig1* and *Olig2* is returned to euploid levels (i.e. two copies) while triplication of the other trisomic genes in the Ts65Dn background is maintained. The cortical interneurons in these Ts65Dn*Olig1/2*<sup>+/-</sup> animals develops like that of their euploid littermates, with normalized values of MGE neurogenesis and inhibitory neuron production [57]. Furthermore, the overinhibition of hippocampal pyramidal neurons found in Ts65Dn mice is rescued in Ts65Dn*Olig1/2*<sup>+/-</sup> mice. Thus, it seems that triplication

of *Olig1* and *Olig2* is necessary for the ventral inhibitory neuron phenotype in Ts65Dn.

Interestingly, however, triplication of *Olig1* and *Olig2* is not sufficient for and may not directly affect synaptic plasticity, at least in the hippocampal DG, because synaptic deficits are observed in Ts1Rhr mice, which are not trisomic for these two genes (Figure 1) [89,90]. Unfortunately, the strength of these deficits has never been directly compared between models, a limitation that applies to behavioral tests as well (Box 2). However, whether triplication of *Olig1* and *Olig2* is involved in electrophysiological changes in the hippocampus and forebrain has not yet been tested. In future studies, it will be important to determine whether correction of defects in the generation of excitatory and inhibitory neurons in Ts65Dn also rescues deficits in spatial learning and memory and in synaptic plasticity. If this is the case, it will indicate that disturbances in neuronal production directly affect cognitive function in DS.

#### **Cerebellar phenotype**

Many features of DS show incomplete penetrance; that is, they are evident in some people but not in others. Where they do occur, they are likely to show variable expressivity and severity. One of the few DS features that occurs to a similar degree in all people with trisomy 21 is a markedly small cerebellum. This finding was recognized before the turn of the 19th century and was expanded on as the microscopic structure of the DS brain was characterized [91]. In a magnetic resonance imaging study of adults with DS, the average cerebellar volume was less than 75% of that in euploid individuals, which is proportionately smaller than the DS brain overall [14]. This volume did not further reduce with age.

Ts65Dn mice also have reduced cerebellar volume [15]. This reduction affects both the molecular layer and the internal granule layer (IGL) and is further characterized by significant reductions in the linear density of Purkinje cells and in the density of granule cell (GC) neurons in the IGL. Following on from the mouse results, GC density was assessed for the first time in DS and shown to be reduced in people with trisomy 21 from 2 to 60 years of age [15]. Both the volume of the IGL (where all cerebellar GC cell bodies reside) and the GC density were reduced by approximately 20% in Ts65Dn mice, which suggests that trisomic mice had approximately 65% as many GC neurons as their euploid counterparts. Surprisingly, Ts65Dn mice do as well as or better than euploid mice on the standard version of the accelerating RotaRod test, a behavioral task designed to test cerebellar functions of balance and motor coordination [15,92], although a unique version requiring the investigator to place mice in the proper orientation on an already-moving rod revealed that Ts65Dn mice were impaired [93]. Another variant of this test, also called by the same name, has been used to test Tc1 mice, which carry most of human chromosome 21 [35]. Different studies using this mouse show either the presence or absence of impairments [36,94]. The authors suggest that genetic background differences might contribute to the different results; variations in experimental technique might also play a role.

### Box 2. Outstanding questions

- How does trisomy affect cerebellar GCPs so as to attenuate the response to SHH? Does a trisomic gene directly affect the canonical pathway in an as yet unrecognized fashion? Does an undefined noncanonical pathway involved in GCP responses to the mitogenic effects of SHH include a trisomic gene? Is part of the effect due to a change in SHH production, release or diffusion?
- It will be particularly important to understand how *DYRK1A* overexpression during the entire phase of embryonic neurogenesis affects cortical morphogenesis and function within the context of many other trisomic genes. One approach would be to assess the developmental consequences of normalizing the gene dosage of *DYRK1A* specifically on the Ts65Dn trisomic background by crossing in a null allele of *DYRK1A*, thereby reducing the number of alleles from three to the normal two copies.
- How does the paucity of excitatory neurons combine with the supernumerary inhibitory neurons to lead to the particular cognitive profile that is specific to DS? To address this question, one approach is to engineer multiple individual gene rescues into trisomic mouse models, as described for *Olig1/2*, and to assess cognition using electrophysiological and behavioral tasks. Upregulation of Hsa21 genes in euploid cultured neurons or downregulation to euploid levels in trisomic cells might provide a faster initial screen. Other models (e.g. worms, flies, zebrafish) might provide additional insights into effects that disrupt normal cell–cell interactions in development and function.
- The possible contributions of *APP* dosage to DS pathology continue to be a major focus of DS research. Overexpression of *APP* in Hsa21, and subsequent changes in the balance of its cleavage products, contribute to the AD pathology in DS, as well as to the retrograde transport of growth factors in basal forebrain cholinergic neurons [127] and to impairment of the proliferation of neural precursors [105].
- A major practical problem, not limited to DS research, is the absence of standardization for electrophysiological and behavioral testing. For DS models, comparisons are made between different mouse models tested in different ways in different laboratories, yet distinct names are not given to the tests. There has never been, for example, a head-to-head comparison of Ts65Dn, Ts1Cje and Ts1Rhr mice using electrophysiological or behavioral assays in the same experiment. This leads to considerable confusion in the literature.
- As in many areas of biomedical research, translation from animal models to the human disorder is a significant challenge. Mice are the highest mammalian model for which there is currently a good genetic model of DS. Although there are clear limitations in extrapolating findings from mice to humans, trisomic mouse models have proven useful in assaying for drugs that affect hippocampal function, including behavioral outcomes. Indeed, results in Ts65Dn mice have led to multiple pilot studies and several clinical trials. A major question is whether the changes that have been observed in mice will have similar effects in humans that result in improved cognitive functions and therapeutic outcomes to allow people with DS a broader range of opportunities, as well as an extended lifespan. This is, of course, the ultimate goal of experiments of the type discussed herein.

### Mechanisms and abnormalities of cerebellar development


The cerebellum is immature at birth and the IGL is absent early in its development. Instead of the IGL, a layer of granule cell precursors (GCPs) forms the external germinal layer (EGL) at the surface of the cerebellum. Beginning prenatally in human gestation and around the day of birth in mice, these GCPs begin dividing rapidly. Cells on the interior side of the EGL leave the cell cycle and migrate inward along Bergmann radial glia to take up a position in the forming IGL and complete their differentiation. This process occurs in the first 2 years of human postnatal life and during the first 3–4 postnatal weeks in mice. Proliferation of GCPs is dependent on the growth factor SHH [95–97].

The cerebellar growth deficit in Ts65Dn mice has been documented morphologically from birth onward [98]. By 1 week after birth, the trisomic cerebellum was reduced in size in every parameter measured and remained so during adulthood (Figure 4). On the day of birth, however, the overall size of the cerebellum and the thickness of the EGL were the same as in euploid animals. Whereas the number of GCPs was the same as in euploid pups, the number of dividing cells was reduced in trisomic pups [98]. When GCPs were isolated from trisomic or euploid cerebella and incubated with increasing amounts of SHH to measure the proliferative response, trisomic GCP cultures had fewer dividing cells at every SHH concentration [94]. Nonetheless, they did respond to SHH in a dosage-sensitive manner. According to these observations, trisomic mice were treated on the day of birth with a small molecule agonist of the SHH pathway (SAG 1.1) [99,100]. Cerebellar morphology and growth parameters were restored to the same level as in euploid animals by postnatal day 6, approximately

one-third of the way through cerebellar development. The mitotic index was also the same as in euploid animals, which suggests that normalized development of the cerebellum would continue as the animals age [98].

It is of obvious interest to determine the duration of these beneficial effects of SHH pathway stimulation. To date, there are no robust phenotypes of trisomy that can be attributed to the reduction in cerebellar GC and Purkinje cells. It was recently reported that individuals with DS display differences in some parameters of vestibulo–ocular reflex compared to age- and gender-matched individuals without DS [101]. It would be interesting to analyze this in trisomic mice, especially in combination with electrophysiological measurements, as has been done for euploid mice [102]. Recent advances in our understanding of the role of the cerebellum in various learning and memory paradigms raises the question of whether restoration of cerebellar structure can correct not only functions that have historically been linked to the cerebellum, but also those attributed to other brain regions in Ts65Dn and DS [103,104].

It has been reported that a C-terminal cleavage product of amyloid precursor protein (APP) can act as an accessory transcription factor of protein patched homolog 1 (Ptch1), the SHH receptor [105]. This occurs in neurospheres derived from the SVZ and hippocampus. *App* is upregulated in the cerebellum of Ts65Dn mice [35] and Ptch is a negative regulator of the pathway, so this could contribute to the attenuated response of cerebellar GCPs to SHH. Several details of the response to SHH and the agonist SAG 1.1 differ between the transient cerebellar GCP population and the long-term neuronal population from which these neurospheres are derived, including lower, not higher levels of Ptch transcripts [105]. Nonetheless, in



**Figure 4. Proliferation deficits in granule cell precursors (GCPs) lead to reduced cerebellar volume.** Fewer mitotic GCP are found in the external granule cell layer (EGL) in mouse models of DS [15,106] and this leads to a paucity of granule cells in the internal granule cell layer (IGL) following their migration inward, past the molecular layer (ML) and Purkinje cell layer (PCL). Reduced granule cell density is also observed in the DS cerebellum. The size of the Purkinje cell population is also reduced in trisomic mouse models [15] and, given the reduction in overall volume of the DS cerebellum [14], this is probably also true in DS. These cell production abnormalities lead to reduced overall cerebellar volume in adult trisomic mice, as shown in the histological sections of euploid (bottom left) and Ts65Dn mouse model (bottom right) [98]. SHH, released by Purkinje cells, is known to influence granule cell production [96,97], and GCP in the Ts65Dn cerebellum exhibit reduced responsiveness to SHH compared to euploid; application of a SHH agonist has been used to correct this proliferation defect in the Ts65Dn cerebellum [98]. Histological stainings adapted, with permission, from [98]. Copyright (2006) National Academy of Sciences, U.S.A.

light of this finding, it is interesting that Ts1Cje mice, which are trisomic for approximately 80% of the genes triplicated in Ts65Dn (but not for *App*; Figure 1) show a similar reduction in cerebellar volume but less of a reduction in GC density than do Ts65Dn mice [106]. Such a finding is consistent with *App* dosage effects on the SHH pathway. Finally, increasingly sophisticated bioinformatics analysis of protein network interactions should prove useful in identifying additional trisomic genes that might contribute to DS phenotypes [107].

### Future prospects

Since 1959, when it was shown that DS results from trisomy 21 [108], a major focus of research has been to identify Hsa21 genes and correlate their overexpression with specific phenotypes of DS. However, the availability of genetically defined mouse models that reflect features of DS has led to a phenotype-based approach that has proven to be revolutionary for the prospects of improved cognition in DS. Behavioral tests have suggested specific brain regions that might be especially affected by trisomy 21. For example, most trisomic models show some degree of impairment in various aspects of spatial memory. Indeed, the poor performance of Ts65Dn in the Morris water maze,

a test of visiospatial integration that is dependent on the hippocampus, led behavioral neuropsychologists to study hippocampal function in children with DS [35,109]. The Arizona Cognitive Test Battery is specifically designed to assess functions rooted in the hippocampus, forebrain and cerebellum in people with DS [110] and this battery is being proposed as a readout in several pending clinical trials.

Electrophysiological studies of mouse models have demonstrated impaired function in the forebrain. As discussed above, the hippocampus of Ts65Dn mice has an imbalance of inhibitory relative to excitatory inputs [83,84]. These inhibitory neurons are GABAergic, and drugs such as pentylentetrazole that antagonize the activity of GABA<sub>A</sub> receptors can restore the electrophysiological imbalance and the ability of mice to perform hippocampal-based tasks, such as novel object recognition [85]. Indeed, efforts are under way to conduct clinical trials in DS with several drugs that are known to target GABA<sub>A</sub> receptors (clinical trial identifier NCT01436955; <http://www.clinicaltrials.gov>) and that have seemed promising in preclinical trials [111].

Although postnatal therapies targeting inhibitory neurotransmission may provide a measure of therapy for DS individuals, it is still unclear how efficacious these strategies will be for long-term improvements and whether they particularly act to offset the developmental changes described here. Several other genes triplicated in DS, including the ion channel subunits encoded by *GRIK1* (glutamate receptor, ionotropic, kainate 1) and *GIRK2* (G-protein-coupled inwardly rectifying potassium channel 2) and the synaptic vesicle trafficking regulator, synaptojanin 1 (*SYNJ1*), may also fundamentally impact neurotransmission and synapse maintenance after birth (Box 1). It will be important for future studies to distinguish between the relative roles of prenatal versus postnatal defects with respect to cognitive dysfunction in DS.

As discussed here, many of the phenotypes observed after birth are a result of gene dosage effects during early development. These early changes in brain formation are likely to substantially affect subsequent developmental events, such as cellular differentiation and synapse formation. Amelioration or prevention of these phenotypes will probably require early intervention. Methods for surgical and/or molecular interventions during late gestation are conceivable and in some cases have already been used, as in the case of surgical repair of cardiac malformations. At present, however, many approaches for the treatment of human fetuses in early gestation are neither technically nor ethically possible, so gene-centric approaches in the prenatal period are limited.

Although encouraging results demonstrate that the DYRK1A inhibitor epigallocatechin gallate (a phenol found in green tea) may improve cognitive function in trisomic animals [112], it remains to be seen whether this therapeutic approach will correct any DYRK1A-associated developmental changes. Increased *OLIG1/2* gene dosage and the role that these transcription factors play in the ventral forebrain phenotype present another possible set of targets. If specific *OLIG1/2* inhibitors can be found, the timing and localization of delivery will still present a challenge because these transcription factors are crucial in specifying proper

development of inhibitory neurons, oligodendrocytes and neural tube. The attenuated response to SHH by GCPs, if it represents a downregulated response by all trisomic cells, may point to a common mechanism that accounts for multiple DS phenotypes. The availability of trisomic mouse models in which development is affected in a similar manner to DS will continue to play a crucial role in elucidating causes and identifying opportunities for therapeutic interventions in this complex disorder.

#### Disclosure statement

R.H.R. is a scientific advisor for Roche Pharmaceuticals, Inc. and a consultant to Elan Corp., plc.

#### Acknowledgments

This work was supported in part by the Down Syndrome Research and Treatment Foundation (R.H.R.), Research Down Syndrome (R.H.R.), the Dana Foundation (T.F.H.) and the National Institute of Child Health & Human Development [R01HD038384 (R.H.R.) and R01HD057580 (T.F.H.)]. The content of this manuscript is the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.

#### References

- Canfield, M.A. *et al.* (2006) National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. *Birth Defects Res. A: Clin. Mol. Teratol.* 76, 747-756
- Ferencz, C. *et al.* (1989) Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. *J. Pediatr.* 114, 79-86
- Levy, J. (1991) The gastrointestinal tract in Down syndrome. *Prog. Clin. Biol. Res.* 373, 245-256
- Fischer-Brandies, H. (1988) Cephalometric comparison between children with and without Down's syndrome. *Eur. J. Orthodont.* 10, 255-263
- Frostadt, W. *et al.* (1971) Craniofacial complex in the trisomy 21 syndrome (Down's syndrome). *Arch. Oral Biol.* 16, 707-722
- Wechsler, J. *et al.* (2002) Acquired mutations in *GATA1* in the megakaryoblastic leukemia of Down syndrome. *Nat. Genet.* 32, 148-152
- Yang, Q. *et al.* (2002) Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *Lancet* 359, 1019-1025
- Chapman, R.S. and Hesketh, L.J. (2000) Behavioral phenotype of individuals with Down syndrome. *Ment. Retard. Dev. Disabil. Res. Rev.* 6, 84-95
- Reeves, R.H. and Garner, C.C. (2007) A year of unprecedented progress in Down syndrome basic research. *Ment. Retard. Dev. Disabil. Res. Rev.* 13, 215-220
- Wetmore, D.Z. and Garner, C.C. (2010) Emerging pharmacotherapies for neurodevelopmental disorders. *J. Dev. Behav. Pediatr.* 31, 564-581
- Rissman, R.A. and Mobley, W.C. (2011) Implications for treatment: GABA<sub>A</sub> receptors in aging, Down syndrome and Alzheimer's disease. *J. Neurochem.* 117, 613-622
- Golden, J.A. and Hyman, B.T. (1994) Development of the superior temporal neocortex is anomalous in trisomy 21. *J. Neuropathol. Exp. Neurol.* 53, 513-520
- Sylvester, P.E. (1983) The hippocampus in Down's syndrome. *J. Ment. Defic. Res.* 27, 227-236
- Aylward, E.H. *et al.* (1997) Cerebellar volume in adults with Down syndrome. *Arch. Neurol.* 54, 209-212
- Baxter, L.L. *et al.* (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. *Hum. Mol. Genet.* 9, 195-202
- Crome, R. *et al.* (1966) A statistical note on cerebellar and brain-stem weight in Down syndrome. *J. Ment. Defect Res.* 10, 69-72
- Jernigan, T.L. and Bellugi, U. (1990) Anomalous brain morphology on magnetic resonance images in Williams syndrome and Down syndrome. *Arch. Neurol.* 47, 529-533
- Raz, N. *et al.* (1995) Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. *Neurology* 45, 356-366
- Becker, L.E. *et al.* (1986) Dendritic atrophy in children with Down's syndrome. *Ann. Neurol.* 20, 520-526
- Benavides-Piccione, R. *et al.* (2004) On dendrites in Down syndrome and DS murine models: a spiny way to learn. *Prog. Neurobiol.* 74, 111-126
- Takashima, S. *et al.* (1989) Dendrites, dementia and the Down syndrome. *Brain Dev.* 11, 131-133
- Petit, T.L. *et al.* (1984) Synaptic development in the human fetus: a morphometric analysis of normal and Down's syndrome neocortex. *Exp. Neurol.* 83, 13-23
- Weitzdoerfer, R. *et al.* (2001) Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. *J. Neural. Transm. Suppl.* 61, 59-70
- Schmidt-Sidor, B. *et al.* (1990) Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. *Clin. Neuropathol.* 9, 181-190
- Marin-Padilla, M. (1976) Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. *J. Comp. Neurol.* 167, 63-81
- Zellweger, H. (1977) *Down syndrome. In Handbook of Clinical Neurology*, North-Holland 367-469
- Kimura, M. *et al.* (2005) Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. *Free Radic. Biol. Med.* 39, 374-380
- Schneider, E.L. and Epstein, C.J. (1972) Replication rate and lifespan of cultured fibroblasts in Down's syndrome. *Proc. Soc. Exp. Biol. Med.* 141, 1092-1094
- Bernert, G. *et al.* (1996) Decreased cyclin dependent kinase in brain of patients with Down syndrome. *Neurosci. Lett.* 216, 68-70
- Guidi, S. *et al.* (2008) Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. *Brain Pathol.* 18, 180-197
- Guidi, S. *et al.* (2011) Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. *Brain Pathol.* 21, 361-373
- Potier, M.C. *et al.* (2006) Transcriptional disruptions in Down syndrome: a case study in the Ts1Cje mouse cerebellum during post-natal development. *J. Neurochem.* 97 (Suppl. 1), 104-109
- Roper, R.J. and Reeves, R.H. (2006) Understanding the basis for Down syndrome phenotypes. *PLoS Genet.* 2, e50
- Pletcher, M.T. *et al.* (2001) Use of comparative physical and sequence mapping to annotate mouse chromosome 16 and human chromosome 21. *Genomics* 74, 45-54
- Reeves, R. *et al.* (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. *Nat. Genet.* 11, 177-183
- O'Doherty, A. *et al.* (2005) An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. *Science* 309, 2033-2037
- Yu, T. *et al.* (2010) A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. *Hum. Mol. Genet.* 19, 2780-2791
- Gardiner, K.J. (2010) Molecular basis of pharmacotherapies for cognition in Down syndrome. *Trends Pharmacol. Sci.* 31, 66-73
- Mo, Z. *et al.* (2007) Human cortical neurons originate from radial glia and neuron-restricted progenitors. *J. Neurosci.* 27, 4132-4145
- Kahlem, P. *et al.* (2004) Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. *Genome Res.* 14, 1258-1267
- Das, I. and Reeves, R.H. (2011) The use of mouse models to understand and improve cognitive deficits in Down syndrome. *Disease Models and Mechanisms* 4, 596-606
- Bradford, H.F. (1995) Glutamate, GABA and epilepsy. *Prog. Neurobiol.* 47, 477-511
- Haydar, T.F. (2005) Advanced microscopic imaging methods to investigate cortical development and the etiology of mental retardation. *Ment. Retard. Dev. Disabil. Res. Rev.* 11, 303-316
- Jamain, S. *et al.* (2003) Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. *Nat. Genet.* 34, 27-29
- Thompson, S.M. *et al.* (1996) Mechanisms underlying the neuropathological consequences of epileptic activity in the rat hippocampus *in vitro*. *J. Comp. Neurol.* 372, 515-528
- Rakic, P. (1972) Mode of cell migration to the superficial layers of fetal monkey neocortex. *J. Comp. Neurol.* 145, 61-83

- 47 Corbin, J.G. *et al.* (2001) Telencephalic cells take a tangent: non-radial migration in the mammalian forebrain. *Nat. Neurosci.* 4 (Suppl.), 1177–1182
- 48 de Carlos, J.A. *et al.* (1996) Dynamics of cell migration from the lateral ganglionic eminence in the rat. *J. Neurosci.* 16, 6146–6156
- 49 Anderson, S.A. *et al.* (1997) Interneuron migration from basal forebrain to neocortex: dependence on *Dlx* genes. *Science* 278, 474–476
- 50 Tamamaki, N. *et al.* (1997) Origin and route of tangentially migrating neurons in the developing neocortical intermediate zone. *J. Neurosci.* 17, 8313–8323
- 51 Ang, E.S., Jr *et al.* (2003) Four-dimensional migratory coordinates of GABAergic interneurons in the developing mouse cortex. *J. Neurosci.* 23, 5805–5815
- 52 Fairen, A. *et al.* (1986) Times of generation of glutamic acid decarboxylase immunoreactive neurons in mouse somatosensory cortex. *J. Comp. Neurol.* 251, 67–83
- 53 Miller, M.W. (1985) Cogeneration of retrogradely labeled corticocortical projection and GABA-immunoreactive local circuit neurons in cerebral cortex. *Brain Res.* 355, 187–192
- 54 Rakic, P. (1974) Neurons in rhesus monkey visual cortex: systematic relation between time of origin and eventual disposition. *Science* 183, 425–427
- 55 Valcanis, H. and Tan, S.S. (2003) Layer specification of transplanted interneurons in developing mouse neocortex. *J. Neurosci.* 23, 5113–5122
- 56 Xu, Q. *et al.* (2004) Origins of cortical interneuron subtypes. *J. Neurosci.* 24, 2612–2622
- 57 Contestabile, A. *et al.* (2007) Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice. *Hippocampus* 17, 665–678
- 58 Chakrabarti, L. *et al.* (2010) Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. *Nat. Neurosci.* 13, 927–934
- 59 Chakrabarti, L. *et al.* (2007) Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. *J. Neurosci.* 27, 11483–11495
- 60 Haydar, T.F. *et al.* (1996) Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. *J. Neurosci.* 16, 6175–6182
- 61 Cheng, A. *et al.* (2004) Concurrent generation of subplate and cortical plate neurons in developing trisomy 16 mouse cortex. *Dev. Neurosci.* 26, 255–265
- 62 Dowjat, W.K. *et al.* (2007) Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. *Neurosci. Lett.* 413, 77–81
- 63 Fuentes, J.J. *et al.* (1997) Genomic organization, alternative splicing, and expression patterns of the *DSCR1* (Down syndrome candidate region 1) gene. *Genomics* 44, 358–361
- 64 Guimera, J. *et al.* (1996) A human homologue of *Drosophila* minibrain (*MNB*) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. *Hum. Mol. Genet.* 5, 1305–1310
- 65 Park, J. *et al.* (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. *Cell Mol. Life Sci.* 66, 3235–3240
- 66 Song, W.J. *et al.* (1996) Isolation of human and murine homologues of the *Drosophila* minibrain gene: human homologue maps to 21q22.2 in the Down syndrome 'critical region'. *Genomics* 38, 331–339
- 67 Hammerle, B. *et al.* (2008) The spatio-temporal and subcellular expression of the candidate Down syndrome gene *Mnb/Dyrk1A* in the developing mouse brain suggests distinct sequential roles in neuronal development. *Eur. J. Neurosci.* 27, 1061–1074
- 68 Hammerle, B. *et al.* (2002) *Mnb/Dyrk1A* is transiently expressed and asymmetrically segregated in neural progenitor cells at the transition to neurogenic divisions. *Dev. Biol.* 246, 259–273
- 69 Okui, M. *et al.* (1999) High-level expression of the *Mnb/Dyrk1A* gene in brain and heart during rat early development. *Genomics* 62, 165–171
- 70 Fotaki, V. *et al.* (2002) *Dyrk1A* haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. *Mol. Cell. Biol.* 22, 6636–6647
- 71 Moller, R.S. *et al.* (2008) Truncation of the Down syndrome candidate gene *DYRK1A* in two unrelated patients with microcephaly. *Am. J. Hum. Genet.* 82, 1165–1170
- 72 Fernandez-Martinez, J. *et al.* (2009) Attenuation of notch signalling by the Down-syndrome-associated kinase DYRK1A. *J. Cell Sci.* 122, 1574–1583
- 73 Kinstrie, R. *et al.* (2006) dDYRK2 and Minibrain interact with the chromatin remodelling factors SNR1 and TRX. *Biochem. J.* 398, 45–54
- 74 Lepagnol-Bestel, A.M. *et al.* (2009) DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. *Hum. Mol. Genet.* 18, 1405–1414
- 75 Maenz, B. *et al.* (2008) Characterization of the human *DYRK1A* promoter and its regulation by the transcription factor E2F1. *BMC Mol. Biol.* 9, 30
- 76 Raich, W.B. *et al.* (2003) Characterization of *Caenorhabditis elegans* homologs of the Down syndrome candidate gene *DYRK1A*. *Genetics* 163, 571–580
- 77 Yabut, O. *et al.* (2010) Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. *J. Neurosci.* 30, 4004–4014
- 78 Yang, E.J. *et al.* (2001) Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. *J. Biol. Chem.* 276, 39819–39824
- 79 Dierksen, M. and de Lagran, M.M. (2006) *DYRK1A* (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis. *ScientificWorldJournal* 6, 1911–1922
- 80 Altafaj, X. *et al.* (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing *Dyrk1A* (minibrain), a murine model of Down's syndrome. *Hum. Mol. Genet.* 10, 1915–1923
- 81 Martinez de Lagran, M. *et al.* (2004) Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. *Neurobiol. Dis.* 15, 132–142
- 82 Tejedor, F.J. and Hammerle, B. (2010) MNB/DYRK1A as a multiple regulator of neuronal development. *FEBS J.* 278, 223–235
- 83 Kleschevnikov, A.M. *et al.* (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. *J. Neurosci.* 24, 8153–8160
- 84 Hanson, J.E. *et al.* (2007) The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. *J. Physiol.* 579, 53–67
- 85 Fernandez, F. *et al.* (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. *Nat. Neurosci.* 10, 411–413
- 86 Butt, S.J. *et al.* (2005) The temporal and spatial origins of cortical interneurons predict their physiological subtype. *Neuron* 48, 591–604
- 87 Flames, N. *et al.* (2007) Delineation of multiple subpallial progenitor domains by the combinatorial expression of transcriptional codes. *J. Neurosci.* 27, 9682–9695
- 88 Nery, S. *et al.* (2002) The caudal ganglionic eminence is a source of distinct cortical and subcortical cell populations. *Nat. Neurosci.* 5, 1279–1287
- 89 Olson, L.E. *et al.* (2004) A chromosome 21 critical region does not cause specific Down syndrome phenotypes. *Science* 306, 687–690
- 90 Belichenko, N.P. *et al.* (2009) The 'Down syndrome critical region' is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. *J. Neurosci.* 29, 5938–5948
- 91 Davidoff, L.M. (1928) The brain in Mongolian idiocy. *Arch. Neurol. Psychiatry* 20, 1229–1268
- 92 Hyde, L.A. *et al.* (2001) Motor learning in Ts65Dn mice, a model for Down syndrome. *Dev. Psychobiol.* 38, 33–45
- 93 Costa, A.C. *et al.* (1999) Motor dysfunction in a mouse model for Down syndrome. *Physiol. Behav.* 68, 211–220
- 94 Galante, M. *et al.* (2009) Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. *Hum. Mol. Genet.* 18, 1449–1463
- 95 Dahmane, N. and Ruiz-i-Altaba, A. (1999) Sonic hedgehog regulates the growth and patterning of the cerebellum. *Development* 126, 3089–3100
- 96 Wallace, V.A. (1999) Purkinje-cell-derived sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. *Curr. Biol.* 9, 445–448

- 97 Wechsler-Reya, R.J. and Scott, M.P. (1999) Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. *Neuron* 22, 103–114
- 98 Roper, R.J. *et al.* (2006) Defective cerebellar response to mitogenic hedgehog signaling in Down syndrome mice. *Proc. Natl. Acad. Sci. U.S.A.* 103, 1452–1456
- 99 Chen, J.K. *et al.* (2002) Small molecule modulation of smoothed activity. *Proc. Natl. Acad. Sci. U.S.A.* 99, 14071–14076
- 100 Frank-Kamenetsky, M. *et al.* (2002) Small-molecule modulators of hedgehog signaling: identification and characterization of smoothed agonists and antagonists. *J. Biol.* 1, 10
- 101 Costa, A.C. (2011) An assessment of the vestibulo-ocular reflex (VOR) in persons with Down syndrome. *Exp. Brain Res.* 214, 199–213
- 102 Migliaccio, A.A. *et al.* (2011) Characterization of the 3D angular vestibulo-ocular reflex in C57BL/6 mice. *Exp. Brain Res.* 210, 489–501
- 103 Burguiere, E. *et al.* (2010) Role of the cerebellar cortex in conditioned goal-directed behavior. *J. Neurosci.* 30, 13265–13271
- 104 Rondi-Reig, L. and Burguiere, E. (2005) Is the cerebellum ready for navigation? *Prog. Brain Res.* 148, 199–212
- 105 Trazzi, S. *et al.* (2011) APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. *Hum. Mol. Genet.* 20, 1560–1573
- 106 Olson, L.E. *et al.* (2004) Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. *Dev. Dyn.* 230, 581–589
- 107 Ma'ayan, A. *et al.* (2006) The cognitive phenotype of Down syndrome: insights from intracellular network analysis. *NeuroRx* 3, 396–406
- 108 Lejeune, J. *et al.* (1959) Etudes des chromosomes somatiques de neuf enfants mongoliens. *C.R. Acad. Sci. (Paris)* 248, 1721–1722
- 109 Pennington, B.F. *et al.* (2003) The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. *Child Dev.* 74, 75–93
- 110 Edgin, J.O. *et al.* (2010) Development and validation of the Arizona Cognitive Test Battery for Down syndrome. *J. Neurodev. Disord.* 2, 149–164
- 111 Braudeau, J. *et al.* (2011) Specific targeting of the GABA-A receptor  $\alpha 5$  subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. *J. Psychopharmacol.* 25, 1030–1042
- 112 Guedj, F. *et al.* (2009) Green tea polyphenols rescue of brain defects induced by overexpression of *DYRK1A*. *PLoS ONE* 4, e4606
- 113 Olson, L.E. *et al.* (2004) A chromosome 21 critical region does not cause specific down syndrome phenotypes. *Science* 306, 687–690
- 114 Sago, H. *et al.* (1998) Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. *Proc. Natl. Acad. Sci. U.S.A.* 95, 6256–6261
- 115 Koo, B.K. *et al.* (1992) Magnetic resonance imaging evaluation of delayed myelination in Down syndrome: a case report and review of the literature. *J. Child. Neurol.* 7, 417–421
- 116 Wisniewski, K.E. and Schmidt-Sidor, B. (1989) Postnatal delay of myelin formation in brains from Down syndrome infants and children. *Clin. Neuropathol.* 8, 55–62
- 117 Sturgeon, X. and Gardiner, K.J. (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. *Mamm. Genome* 22, 261–271
- 118 Vilardell, M. *et al.* (2011) Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. *BMC Genomics* 12, 229
- 119 Salehi, A. *et al.* (2006) Increased *App* expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. *Neuron* 51, 29–42
- 120 Lipsky, R.H. and Goldman, D. (2003) Genomics and variation of ionotropic glutamate receptors. *Ann. N. Y. Acad. Sci.* 1003, 22–35
- 121 Buccafusca, R. *et al.* (2008) Characterization of the null murine sodium/myo-inositol cotransporter 1 (*Smit1* or *Slc5a3*) phenotype: myo-inositol rescue is independent of expression of its cognate mitochondrial ribosomal protein subunit 6 (*Mrps6*) gene and of phosphatidylinositol levels in neonatal brain. *Mol. Genet. Metab.* 95, 81–95
- 122 Rezai, Z. and Yoon, C.H. (1972) Abnormal rate of granule cell migration in the cerebellum of 'Weaver' mutant mice. *Dev. Biol.* 29, 17–26
- 123 Westmark, C.J. and Malter, J.S. (2007) FMRP mediates mGluR5-dependent translation of amyloid precursor protein. *PLoS Biol.* 5, e52
- 124 Cramer, N.P. *et al.* (2010) GABAB-GIRK2-mediated signaling in Down syndrome. *Adv. Pharmacol.* 58, 397–426
- 125 Arron, J.R. *et al.* (2006) NFAT dysregulation by increased dosage of *DSCR1* and *DYRK1A* on chromosome 21. *Nature* 441, 595–600
- 126 Martin, L.J. (2007) Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. *Rev. Neurosci.* 18, 115–136
- 127 Salehi, A. *et al.* (2009) Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. *Sci. Transl. Med.* 1, 7ra17